TrialEuropean urology2020

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

Karim Fizazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.